Afatinib is an effective standard treatment for NSCLC associated with activating EGFR mutations [55], and it has shown potential in a Drosophila lung tumor model associated with EgfrCA expression [41]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.